“…Future areas of interest include: (a) epidemiological or clinical research with additional cardiovascular endpoints—including electrocardiogram or echocardiogram measurements; (b) clinical and experimental work that focuses on vulnerable patient populations—including those with congenital heart defects, cardiomyopathies, or cardiac arrhythmias, as chemical exposures may contribute to cardiovascular dysfunction; (c) clinical and experimental work focused on neonatal, infant and pediatric populations—as cardiac, autonomic and metabolic systems continue to develop and mature after birth; (d) use of (nonrodent) experimental models that better replicate human electrophysiology; (e) studies that explore the effects of bisphenol and phthalate mixtures (or studies that take into account a pediatric patient's “exposome”); and finally, (f) comparative studies that examine the cardiac safety profile of alternative chemicals. The latter is particularly important as we move toward adopting BPA and DEHP substitutes, without a thorough understanding of their safety or impact on cardiovascular health (M. Ferguson, Lorenzen‐Schmidt, & Pyle, 2019; Gao, Ma, Chen, & Wang, 2015; Lozano & Cid, 2013; Trasande, 2017; van der Meer et al, 2014). Through comprehensive examination of bisphenol and phthalate toxicity in vulnerable populations, protective measures or mitigation strategies may be revealed and implemented.…”